Side-by-side · Research reference
DermorphinvsSNAP-8
Side-by-side comparison across mechanism, dosage, evidence, side effects, administration, and stack synergies. Citations on every claim where available.
AAnimal-StrongHUMAN-REVIEWED20/47 cited
BHuman-MechanisticHUMAN-REVIEWED8/46 cited
Dermorphin
Opioid Peptide · μ-Receptor Agonist · Research Only
Research only · ICV / SC (animal models)
SNAP-8
Synthetic Octapeptide · Cosmetic Topical
TopicalRoute
8-AAPeptide length
SNAREPrimary target
Topical · Facial application · Twice daily
01Mechanism of Action
Parameter
Dermorphin
SNAP-8
Primary target
μ-opioid receptors (central and peripheral)Negri 1992Steel 2014
SNARE complex (SNAP-25 competitive binding site)
Pathway
μ-receptor activation → G-protein coupling → adenylyl cyclase inhibition → neuronal hyperpolarization
Acetyl octapeptide-3 → SNARE complex disruption → Reduced vesicular fusion → Decreased acetylcholine release → Muscle relaxation
Downstream effect
Potent analgesia, reduced nociceptive signaling, opioid-mediated CNS and peripheral effects
Transient reduction in neuromuscular signal transmission, decreased muscle contraction amplitude, wrinkle depth reduction
Feedback intact?
N/A — exogenous opioid agonist
N/A — topical cosmetic, no systemic endocrine axis
Origin
Phyllomedusa sauvagei and P. bicolor frog skin — gene-encoded with natural D-amino acid incorporationAmiche 1998Mignogna 1992
Synthetic peptide derived from N-terminal fragment of SNAP-25 protein (synaptosomal-associated protein 25 kDa)
02Dosage Protocols
Parameter
Dermorphin
SNAP-8
Legal status
Controlled substance in many jurisdictions · Research only
Not approved for human use.
—
Animal research (ICV)
Low nanomolar to picomolar range
Intracerebroventricular administration in rodent models.
—
Detection limit (doping)
5 pg/mL in equine plasma/urineSteel 2014
High-throughput LC-MS/MS screen developed for racing industry.
—
Duration of action
10–120 minutes (dose-dependent, intrathecal)
—
Evidence basis
Animal studies · In vitro assays
RCT, in vitro skin penetration studies
Human toxicity
Kambô ritual (P. bicolor skin) — violent emesis, vasodilation, fluid shifts, ADH dysregulationTran 2025
—
Typical concentration
—
2–10% in cosmetic formulationsLupin 2024Raikou 2017
Commercial products typically use 5–10%.
Treatment duration
—
20–60 days for visible effectRaikou 2017
Skin microtopography improvements measured at 20-day intervals.
Formulation type
—
Oil-in-water emulsion, serum, cream
Application site
—
Facial skin — glabellar lines, crow's feet, forehead
03Metabolic / Fat Loss Evidence
04Side Effects & Safety
Parameter
Dermorphin
SNAP-8
Opioid effects
Respiratory depression, sedation, euphoria, tolerance, dependence risk
—
Kambô ritual toxicity
Violent emesis, vasodilation, profound fluid shifts, hyponatremia, ADH dysregulation, brain death (case report)Tran 2025
—
Receptor selectivity caveat
Two μ-receptor subtypes — differential behavioral effects (analgesia vs. catalepsy)Negri 1992
—
Proteolytic stability
Tyr³-Pro⁶ bond relatively unstable; endogenous enzymes may produce tetrapeptide fragmentsCucumel 1996
—
Cytotoxicity
—
Concentration-dependent antiproliferative effect observed in vitro; IC50 ~10 mg/mL (argireline, 6-AA analogue)
Commercial formulations typically use 0.05–0.1 mg/mL, well below cytotoxic threshold.
Skin irritation
—
Minimal; well-tolerated in clinical use
Peptide oxidation
—
Methionine residue susceptible to oxidation in formulation; may reduce efficacyKluczyk 2021
Formulation stability issue, not a direct adverse effect.
Hypersensitivity
—
Rare; no widespread allergic reactions reported
Absolute Contraindications
Dermorphin
- ·Human use — not approved by any regulatory authority
- ·Controlled substance status — possession illegal in many jurisdictions
- ·Known opioid hypersensitivity or respiratory compromise
SNAP-8
- ·Known hypersensitivity to acetyl octapeptide-3 or formulation excipients
Relative Contraindications
Dermorphin
- ·Any context outside approved animal research protocols
- ·CNS depressant co-administration
SNAP-8
- ·Active skin infections or open wounds at application site
- ·Neuromuscular disorders (theoretical concern, no documented cases)
05Administration Protocol
Parameter
Dermorphin
SNAP-8
1. Legal and ethical framework
Dermorphin is a controlled substance in many jurisdictions and is not approved for human use. Possession, synthesis, or distribution may be illegal. Use is restricted to licensed research settings under institutional review.
Wash face with gentle cleanser and pat dry. Remove makeup and surface oils to optimize peptide contact.
2. Animal research protocols
In rodent models, intracerebroventricular (ICV) or intrathecal injection is used at nanomolar to picomolar concentrations. Subcutaneous administration also documented. All protocols require IACUC approval.
Apply 1–2 drops or pea-sized amount of SNAP-8 serum or cream to target areas (forehead, glabellar lines, crow's feet). Gently massage until absorbed.
3. Analytical detection
High-throughput LC-MS/MS screens developed for anti-doping programs detect dermorphin and 17 related peptides in equine and human urine/plasma at limits as low as 5 pg/mL.Steel 2014
Twice daily — morning and evening. Allow 2–3 minutes for absorption before applying additional skincare products.
4. Kambô ritual (traditional use)
Application of Phyllomedusa bicolor skin secretions to superficial burns. Not recommended — associated with severe toxicity including violent emesis, hyponatremia, and documented case of brain death.Tran 2025
Apply before heavier creams or occlusive moisturizers. Peptides penetrate best from water-based serums on clean skin.
5. Storage
—
Store at room temperature, away from direct sunlight. Refrigeration may extend shelf life of formulations containing unstable peptides.
6. Duration
—
Consistent use for 20–60 days required for visible wrinkle reduction. Effects are temporary and reverse upon discontinuation.